Get the Stockscreener App
13.53
0.11%
0.015
Arcutis Biotherapeutics Inc stock is traded at $13.53, with a volume of 1.98M.
It is up +0.11% in the last 24 hours and down -7.14% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$13.52
Open:
$13.5
24h Volume:
1.98M
Relative Volume:
0.81
Market Cap:
$1.82B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-3.4515
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
-11.22%
1M Performance:
-7.14%
6M Performance:
+25.05%
1Y Performance:
+68.70%
1-Day Range:
$13.15
$13.93
1-Week Range:
$12.42
$15.67
52-Week Range:
$6.99
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
13.53 | 1.82B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Arcutis outlines growth potential with ZORYVE expansions and market penetration - MSN
Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates - MSN
Arcutis Biotherapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Call Transcript - Insider Monkey
Arcutis Biotherapeutics Reports Strong Q1 Earnings Growth - TipRanks
Jefferies lifts Arcutis stock target to $20 on strong sales By Investing.com - Investing.com South Africa
ZORYVE foam shows promise in psoriasis treatment By Investing.com - Investing.com South Africa
ZORYVE foam shows promise in psoriasis treatment - Investing.com Australia
Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements - TipRanks
Arcutis Biotherapeutics (ARQT) Reports Positive Phase 3 Trial Results for Psoriasis Treatment | ARQT Stock News - GuruFocus
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology - The Manila Times
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology | ARQ - GuruFocus
Jefferies lifts Arcutis stock target to $20 on strong sales - Investing.com Australia
Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Decoding Arcutis Biotherapeutics Inc (ARQT): A Strategic SWOT In - GuruFocus
Arcutis Biotherapeutics Reports Strong Q1 2025 Growth - TipRanks
Arcutis (ARQT) Reports Strong Q1 Growth on Rising ZORYVE Demand - GuruFocus
Earnings call transcript: Arcutis Biotherapeutics Q1 2025 earnings beat estimates - Investing.com
Earnings call transcript: Arcutis Biotherapeutics Q1 2025 earnings beat estimates By Investing.com - Investing.com India
Arcutis Biotherapeutics stock falls despite Q1 revenue beat By Investing.com - Investing.com Canada
Arcutis Biotherapeutics stock falls despite Q1 revenue beat - Investing.com
Arcutis Biotherapeutics (ARQT) Q1 Performance Surpasses Expectations - GuruFocus
Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings: EPS Loss of $0.20 Beats Estimate, Revenue Surpasses Forecast at $63.8 Million - GuruFocus
Arcutis Q1 2025 slides: Revenue soars 196% YoY despite seasonal headwinds - Investing.com India
ARCUTIS BIOTHERAPEUTICS Earnings Results: $ARQT Reports Quarterly Earnings - Nasdaq
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Arcutis Biotherapeutics (ARQT) Surpasses Q1 Revenue Expectations with Robust Growth | ARQT Stock News - GuruFocus
Earnings Flash (ARQT) Arcutis Biotherapeutics Reports Q1 Revenue $65.8M, vs. FactSet Est of $62.2M - marketscreener.com
Arcutis Q1 Earnings: ZORYVE Sales Surge 196% to $64M as Coverage Expands | ARQT Stock News - Stock Titan
Arcutis Biotherapeutics (ARQT) Q1 Earnings Preview - GuruFocus
How to Take Advantage of moves in (ARQT) - news.stocktradersdaily.com
What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 E - GuruFocus
Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com
What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings - GuruFocus
Biotech Stocks Facing FDA Decision In July - RTTNews
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News - GuruFocus
Arcutis Awards Major Stock Package: 26,500 RSUs to Three New Hires Under Nasdaq Rule - Stock Titan
Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? - MSN
Learn to Evaluate (ARQT) using the Charts - news.stocktradersdaily.com
Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets - Seeking Alpha
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 - The Manila Times
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Is Breakeven Near? - simplywall.st
Arcutis Biotherapeutics Appoints New Chief Financial Officer - MSN
Arcutis Announces Chief Financial Officer Transition | ARQT Stoc - GuruFocus
Arcutis Biotherapeutics (ARQT) Announces CFO Transition - GuruFocus
Arcutis Biotherapeutics (ARQT) Announces Transition in CFO Role - GuruFocus
Arcutis Names New Chief Financial Officer - Contract Pharma
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):